Crossmark

Combination therapy with erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy: an open-label pilot study to assess the safety and feasibility

Crossref DOI link: https://doi.org/10.1186/s12887-018-1389-z

Published Online: 2019-01-08

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nonomura, Miho

Harada, Sayaka

Asada, Yuki

Matsumura, Hisako

Iwami, Hiroko

Tanaka, Yuko

Ichiba, Hiroyuki http://orcid.org/0000-0002-1272-1046
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development
License Information

Text and Data Mining valid from 2019-01-08

Version of Record valid from 2019-01-08
More Information

Article History

Received: 14 September 2018

Accepted: 28 December 2018

First Online: 8 January 2019

Ethics approval and consent to participate

: The present study was approved by the intuitional ethics committee at the Osaka City General Hospital (1306022). Parental consent was obtained before the registration to the study.

: This study adheres to CONSORT guidelines.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below